Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-escalation study of NMB46 (regadenoson) during cardiac catheterization
jRCT2080224182Phase 2Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regadenoson in coronary arteriosclerosis (3 arms), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Effect of NMB46 on coronary blood flow and Safety and tolerability of NMB46. Started Dec 2018; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2080224182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224182.